YI-MAB Biotech Hong Kong

I-Mab is a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly in oncology and autoimmune disorders. The company has established a robust pipeline of over 10 clinical and pre-clinical assets, leveraging its proprietary antibody engineering platforms to create next-generation therapeutics. I-Mab operates with a dual-hub strategy, maintaining significant research and development footprints in both China and the United States. Its lead asset, felzartamab, has demonstrated significant potential in multiple myeloma and autoimmune kidney diseases, while its broader portfolio includes innovative bispecific antibodies and checkpoint inhibitors.